ENTITY

MetaVia (MTVA US)

7
Analysis
Health CareUnited States
MetaVia Inc. operates as a clinical-stage biotechnology company. The Company focuses on developing dual oxyntomodulin (OXM) analog agonist for the treatment of obesity and metabolic dysfunction-associated steatohepatitis (MASH). MetaVia serves customers worldwide.
more
Publication Icon
No publications yet
There aren’t any Insights right now
Back to "All"
x